Non-small cell lung cancer+2
RecruitingStudy on THIO and Cemiplimab for Patients with Advanced Non-Small Cell Lung Cancer
Study on THIO and Cemiplimab for Patients with Advanced Non-Small Cell Lung Cancer
- Disease:Non-small cell lung cancerNon-small cell lung cancer stage III+1
- Substances:Cemiplimab2-Amino-9-((2R,4R,5R)-4-Hydroxy-5-(Hydroxymethyl) Tetrahydrofuran-2-Yl)-1,4,5,9-Tetrahydro-6H-Purine-6-Thione
Hungary- Participants:18–64 years · 65+ years
- Substances:Cemiplimab
- Sponsor:Maia Biotechnology Inc.










